



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|---------------|----------------------|---------------------|---------------------|
| 10/532,498 | 04/25/2005 | Chizu Murai | 270650US0PCT | 4290 |
| 22850 | 7590 | 09/16/2009 | | |
| OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P. | | | | EXAMINER |
| 1940 DUKE STREET | | | | WEDDINGTON, KEVIN E |
| ALEXANDRIA, VA 22314 | | | | ART UNIT |
| | | | | PAPER NUMBER |
| | | | | 1614 |
| NOTIFICATION DATE | DELIVERY MODE | | | |
| 09/16/2009 | ELECTRONIC | | | |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

| | | |
|------------------------------|--------------------------------------|-------------------------------------|
| Office Action Summary | Application No. 10/532,498 | Applicant(s) MURAI, CHIZU |
| | Examiner KEVIN WEDDINGTON | Art Unit 1614 |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 19 June 2009.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 7,9,11,13,19,20 and 22-25 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) 24 and 25 is/are allowed.

6) Claim(s) 7,11,13,19 and 20 is/are rejected.

7) Claim(s) 9, 22 and 23 is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No./Mail Date 6-19-09

4) Interview Summary (PTO-413)
Paper No./Mail Date. _____

5) Notice of Informal Patent Application

6) Other: _____

Claims 7, 9, 11, 13, 19, 20 and 22-25 are presented for examination.

Applicant's amendment, response and information disclosure statement filed June 19, 2009 have been received and entered.

Allowable Subject Matter

Claims 24 and 25 are allowable.

Claim Objections

Claims 9, 22 and 23 are objected to as being dependent upon a rejected base claim 7.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 7, 11, and 19 are again rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

This is a written description rejection.

A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559,

1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species); *In re Ruschig*, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967).

An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.

In particular, the specification as original filed fails to provide sufficient written bases of any of the agents demonstrating wherein possession of use of the broad terms: **a basic physiologically active substance, one or more enteric polymer having acidic residues in the molecule thereof, and one or more electrolytes selected from the group consisting of an alkali earth metal salt or an alkaline earth metal salt.** The mere fact that Applicant may have discovered one type of basic physiologically active substance formulated into a multilayered tablet with the other components is not sufficient to claim the entire genus.

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics

coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.

A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]."

Claims 7, 11 and 19 are again not allowed.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 7 is again rejected under 35 U.S.C. 102(b) as being anticipated by Fukui et al. (4,772,475), of record, for reason of record as set forth in the previous Office action dated March 19, 2009 at pages 4-5 as applied to claim 1 (should be claim 7).

Applicant's remarks regarding the prior art does not teach every component of the instant basic medicine-containing preparation are not persuasive since the composition step forth in the prior art broadly teaches any basic physiologically active

substance such as dl-tamsulosin, broadly teaches any one or more enteric polymers having acidic residues in the molecule thereof such as hydroxypropylmethyl cellulose phthalate and hydroxypropylmethyl cellulose acetate succinate, and broadly teaches alkali metal salt and an alkaline earth metal salt such as magnesium stearate and calcium stearate. Note that a composition comprising the same agents (components) as the claimed composition will inherently possess the qualities recited therein.

Claim 7 would be allowable by the incorporation of the objected claims 9, 22 and 23 into claim 7.

The rejection made under 35 USC 102(b) is adhered to.

Claim 7 is not allowed.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 7, 11, 13, 19 and 20 are again rejected under 35 U.S.C. 102(a) as being anticipated by WO 03/039530 A1, AO of PTO-1449, hereby known as Platteeuw et al., of record, for reason for record as set forth in the previous Office action dated March 19, 2009 at pages 5-6 as applied to claims 7-21.

Applicants' remarks regarding the prior art's "one or more electrolyte selected from the group consisting of an alkali metal salt or an alkaline earth metal salt" is not the "highly dissolved in an aqueous solvent" are not persuasive since the claims do not

recite the "critical limitation", especially claim 7. Claim 7 stills broadly reads on any alkali metal salt and an alkaline earth metal salt wherein calcium phosphate is such an electrolyte.

The rejection made under 35 USC 102(a) is adhered to.

Claim 7, 11, 13, 19 and 20 are not allowed.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN WEDDINGTON whose telephone number is (571)272-0587. The examiner can normally be reached on 12:30 pm - 9:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571)272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

KEVIN WEDDINGTON
Primary Examiner
Art Unit 1614

/KEVIN WEDDINGTON/
Primary Examiner, Art Unit 1614